New stroke device aims to restore blood flow in distal brain clots
NCT ID NCT05152524
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial tests a device called Tigertriever 13 to treat distal ischemic strokes, where a blood clot blocks a small artery deep in the brain. About 168 patients with disabling symptoms will receive either the device or standard medical care within 24 hours of stroke onset. The goal is to see if the device safely restores blood flow and improves outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tigertriever 13 device
What this could lead to
If successful, this device could offer a new treatment option for distal ischemic strokes, potentially improving blood flow and reducing disability.
What could go wrong
This is an early-stage study with 168 participants, so results may not apply to everyone. There are risks of bleeding or other complications from the procedure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ISCHEMIC STROKE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Advocate Aurora Research Institute,
Chicago, Illinois, 60657, United States
-
Alfreid Krupp
Essen, Germany
-
CUB Hôpital Erasme
Brussels, 1070, Belgium
-
Corewell Health (Spectrum)
Grand Rapids, Michigan, 49085, United States
-
Lakewood Regional Medical Center
Los Angeles, California, 90013, United States
-
Los Robles
Thousand Oaks, California, 91360, United States
-
Mercy Health
Toledo, Ohio, 43604, United States
-
Mount Sinai
New York, New York, 10029, United States
-
Munson Medical Center
Traverse City, Michigan, 49684, United States
-
NYU Langone Health
New York, New York, 10016, United States
-
Orebro University Hospital
Örebro, Sweden
-
Semmes Murphey Foundation
Memphis, Tennessee, 38120, United States
-
St. Lukas hospital, Radprax
Solingen, 42697, Germany
-
Stony Brook University
Stony Brook, New York, 11794, United States
-
Texas Stroke Institute
Plano, Texas, 75075, United States
-
University of Buffalo
Buffalo, New York, 14203, United States
-
Universitätsklinikum Bonn
Bonn, 53127, Germany
-
Universitätsklinikum Schleswig-Holstein
Kiel, Germany
-
Valley Baptist Medical Center
Harlingen, Texas, 78550, United States
-
WellStar Research Institute
Marietta, Georgia, 30060, United States